Who is sponsoring NCT05203120?

NCT05203120 is sponsored by University of Aarhus.

What drugs are being tested in NCT05203120?

Interventions in NCT05203120: Proton therapy.

What condition does NCT05203120 study?

NCT05203120 studies Hepatocellular Carcinoma.

Is NCT05203120 still recruiting?

NCT05203120 is currently recruiting now. Last updated 11 May 2023.

Last reviewed 2023-05-11 · How we verify

NCT05203120

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma

Recruiting now NA Last updated 11 May 2023

What this trial tests

NA trial testing Proton therapy in Hepatocellular Carcinoma in 50 participants. Currently enrolling.

Timeline

1 April 2022

Primary endpoint
31 December 2025

1 January 2030

Quick facts

Lead sponsor	University of Aarhus
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 April 2022
Primary completion	31 December 2025
Estimated completion	1 January 2030
Sites	3 locations across Denmark

Drugs / interventions tested

Proton therapy

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

University of Aarhus

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

350 new cases of hepatocellular carcinoma (HCC) are diagnosed in Denmark each year, but the overall prognosis is poor with a 1-year survival rate of less than 40% and a 5-year survival rate of 10% for the entire patient group. This national phase II non-randomized single-arm study of proton therapy in HCC is conducted with the aim to offer a safe and efficient radiation treatment to fragile patients with reduced dose to the normal liver compared to conventional photon-based radiotherapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Predictive Model of Liver Toxicity to Aid the Personalized Selection of Proton Versus Photon Therapy in Hepatocellular Carcinoma.
Chamseddine I, Kim Y, De B, Naqa IE, et al · · 2023 · cited 10× · PMID 36739920 · DOI 10.1016/j.ijrobp.2023.01.055
Intrafraction tumor motion monitoring and dose reconstruction for liver pencil beam scanning proton therapy.
Nankali S, Worm ES, Thomsen JB, Stick LB, et al · · 2023 · cited 7× · PMID 36937392 · DOI 10.3389/fonc.2023.1112481
Proton therapy in the treatment of hepatocellular carcinoma.
Dionisi F, Scartoni D, Fracchiolla F, Giacomelli I, et al · · 2022 · cited 2× · PMID 36003769 · DOI 10.3389/fonc.2022.959552

Verify or expand the search:

Other trials of Proton therapy

Trials testing the same drug.

NCT07412314 — Proton Therapy for Recurrent Nasopharyngeal Carcinoma · NA · recruiting
NCT06462378 — Proton Therapy for Locally Advanced Cervical Cancer · Phase 2 · recruiting
NCT05350475 — Protons Vs. Photons for High-risk Prostate Cancer · NA · recruiting
NCT03018418 — Proton Therapy in Reducing Toxicity in Anal Cancer · Phase 2 · active not recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05203120 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 11 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05203120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing